Abstract. Expression of P-glycoprotein, a phylogenetically conserved integral plasma membrane protein, is implicated as one of the most important factors contributing to tumor cell multidrug resistance. Formalin-fixed, paraffin-embedded normal and neoplastic canine tissues were studied using an avidin-biotin complex technique employing three murine monoclonal antibodies (C494, C2 19, JSB-1) to different epitopes of the P-glycoprotein molecule. Evaluation of immunostaining of normal canine tissues revealed positive labeling detected by each antibody in the liver, proximal renal tubular epithelium, adrenal cortex, colonic epithelium, and capillary endothelial cells of the brain. A total of 166 tumors of epithelial or mesenchymal origin were evaluated for P-glycoprotein immunoreactivity. Hepatomas (4/4), colorectal adenomas (7/7), colorectal carcinomas (4/4), adrenal cortical adenomas (3/3), hemangiopericytomas (1 5/ 15), apocrine gland adenocarcinomas (4/5, go%), and transitional cell carcinomas (2/2) consistently labeled with at least one of the antibodies. Histiocytomas (0/ lo), cutaneous plasma cell tumors (0/10), fibromas (0/3), fibrosarcomas (0/4), and leiomyomas (0/4) were uniformly negative with all antibodies. Malignant lymphomas (6/22, 27.3%), malignant melanomas (4/13, 30.8%), leiomyosarcomas (3/6, 50°/o), mammary gland carcinomas (1 2/ 19, 63.2%), mammary gland adenomas (3/9, 33.3%), squamous cell carcinomas @/lo, go%), basal cell tumors (5/7, 71.4%), apocrine gland adenomas (1/2, So%), cholangiocarcinomas (2/3, 66.7%), and thyroid gland carcinomas (2/4, 50%) gave variable results. The antibodies C494, JSB-1, and C219 labeled 66/166 (39.8%), 53/166 (31.9%), and 38/166 (22.9%) of all tumors studied, respectively. A total of 26/166 (15.7%), 22/166 (13.3%), and 371166 (22.6%) of tumors were labeled by all three, just two, or one antibody alone, respectively. The antibody C494 was the only antibody labeling 28/166 (16.9%) of the cases. JSB-I alone labeled 9/166 (5.4%) of the tumors. C219 failed to label any tumors not also labeled by either C494 or JSB-I. Labeling by C494 was more intense and specific than labeling by the other two antibodies. Results indicate that P-glycoprotein can be detected in routinely processed canine tissues. The detection of P-glycoprotein within canine liver, kidney, adrenal gland, and colon and within tumors arising from these tissues is consistent with that reported in the literature for human tissues. Variable labeling results of other tumors such as malignant lymphoma and mammary gland carcinomas also is consistent with reports of human studies. Detection of multidrug resistance markers such as P-glycoprotein in canine tissues may provide additional information upon which to base a prognosis or to design treatment regimens for canine tumors.
The single most important factor contributing to cancer treatment failure is tumor cell drug resist a n~e . ' ,~,~~ Clinical drug resistance is defined as the ability of tumor cells to survive exposure to toxic agents at maximum doses tolerated by normal Multidrug resistance refers to simultaneous resistance to a variety of cytotoxic agents that have different targets and diverse chemical structures. 28 Multidrug resistance can be an intrinsic property of tumor cells or may be acquired by populations of tumor cells that were initially sensitive to chemotherapy but subsequently become resistant after exposure to cytotoxic agents.I5J5 One of the most highly studied mechanisms of multidrug resistance is referred to as classical multidrug resistance (MDR) and is attributed to mutation or amplification of genes encoding a high-molecularweight integral membrane protein, P-glycoprotein (P-gly).4,15, 19, 28 P-gly molecules have been identified and implicated in drug resistance in organisms as diverse as Leishmania, Plasmodium, hamsters, mice, cultured canine cells, and human being^.^,^^,^^,^^,^^ In humans and ro-Ginn Vet Pathol 3 3 3 , 1996 dents, P-glycoproteins have multiple isoforms encoded by families of genes referred to as the MDR genes (mdrl, mdr2, mdr3). 25, 30, 32 The intron-exon structure of the human and mouse mdrl genes have been shown to be virtually i d e n t i~a l .~~,~~ The human mdr2 and mdr3
genes are homologous and are equivalent to the mouse mdr2. 28, 30 The isoform in humans known to confer multidrug resistance is encoded by the mdrl gene. 30.35 It is not known whether the isoform encoded by the other human mdr gene (mdr2/mdr3) contributes to drug r e~i s t a n c e .~~,~~ The gene for P-gly has been cloned (mdrl) and proven to confer multidrug resistance in tumor cells by transfection studies in which transfer of this single gene from the MDR gene family produced a clone of drug-resistant cell^.^^'^^ P-gly is thought to function as an energy dependent efflux pump, effectively decreasing the intracellular accumulation of cytotoxic agents in tumor cell^.^^^^^ Structure and function studies of P-gly molecules in other vertebrates and eukaryotes support this con~e p t .~~,~~
The exact physiologic role of P-gly and factors controlling its expression or selectivity are not yet known.
P-gly can be detected in human tissues by hybridization techniques, immunoblotting, or immunohistochemical m e t h o d~.~J~J~,~~,~~ P-gly in normal human tissues is expressed on the canalicular surface of hepatocytes, on the apical surface of proximal tubule cells of the kidney, in pancreatic ductules, on the mucosal surfaces of the small and large intestine, and in sebaceous glands of the skin, the endometrium of the gravid uterus, placental trophoblasts, cells of the adrenal cortex, and capillary endothelial cells of tissues considered to be pharmacologic sanctuaries (testis, brain).13J4, 24, 25 Preliminary studies of cancer in humans indicate that a significant number ofpatients that develop drugresistant neoplasms do express P-gly in tumor ce11s.7J2J3J5~24~27 Patterns of P-gly expression in human tumors fall into four ~a t e g o r i e s .~~,~~ The first is those tumors with intrinsic P-gly expression.I3 These tumors are derived from cells that express P-gly in the nonneoplastic state and are also traditionally refractory to treatment by drugs affected by the MDR phenomenon. 13,15,24, 25 The second category, tumors with occasional expression, includes various leukemias, nonHodgkin's lymphoma, and some breast tumors. 13, 24, 25 These tumors are normally considered to be initially susceptible to c h e m~t h e r a p y . l~J~,~~,~~ The third category, tumors with extremely rare P-gly expression and variable sensitivity to chemotherapy, comprises most breast tumors, melanomas, and tumors of the urinary bladder, thyroid, thymus, ovary, and p r~s t a t e . '~.~~ The fourth category includes tumors that are thought to have acquired expression after treatment.13,30 Intermediate grade non-Hodgkin's lymphoma, multiple myeloma, acute myeloid leukemias, soft tissue sarcomas of childhood, ovarian tumors, and neuroblastomas comprise this category. P-gly expression within certain tumors of this group has been associated with poor prognosis, disease progression, or predictable multidrug r e~i s t a n c e .~,~,~,~~
The purposes of this study were to 1) determine whether or not P-gly expression can be detected with immunohistochemical methods in canine tissues routinely processed for histopathology, 2) define optimal immunohistochemical protocols to detect P-gly in canine tissues, 3) determine the tissue distribution and intracellular location of P-gly expression in normal canine tissues and compare these findings with those reported in the literature for P-gly expression in human tissues, and 4) survey a variety of routinely processed benign and malignant canine neoplasms for P-gly expression.
Materials and Methods

Tissues
Normal canine tissues were collected from young adult male and female dogs (approximately 2-5 years old) euthanatized with intravenous barbiturate by local animal control agency representatives. Animals in this group had been previously selected for euthanasia by the agency and were not euthanatized for the purpose of this study. Use of tissues from these animals was approved by the University of Florida Institutional Animal Care and Use Committee. Tissues were fixed for 24-48 hours in 10% neutral buffered formalin, routinely processed, and embedded in paraffin wax. Normal tissues collected for immunostaining are listed in Table 1 .
One hundred sixty-six tumor tissue samples were obtained from formalin-fixed, paraffin-embedded specimens from the University of Florida College of Veterinary Medicine surgical pathology files. Benign and malignant neoplasms of both epithelial and mesenchymal origin were included (Table 2) . Five-micrometer sections from paraffin blocks of each group were mounted on Silane (Sigma Chemical Co., St. Louis, M0)-treated slides prior to immunostaining.
Antibodies
The reactivity of three murine-origin IgG subclass monoclonal antibodies (Signet Laboratories, Dedham, MA), C2 19, C494, and JSB-1, each recognizing a different and spatially distinct cytoplasmic epitope of the human P-gly molecule, was determined for each tissue examined. Table 3 lists the antibody source and specificity of each antibody. C494 is specific for mdr I , and C2 19 and JSB-1 recognize both mdr 1 and mdr3, according to the distributor. One researcher reported the possibility that JSB-1 was specific for mdrl and did not recognize mdr3, but this report was not c o n c I~s i v e .~~ Optimum primary antibody dilution and incubation times were determined by initial trials of serial dilutions (1 : 10, 1 : 20, 1 : 40, 1 : 100, 1 : 200, 1 : 400) of each antibody carried out at incubation times of 1 hour, 3 hours, and overnight 
Immunohistochemistry and antigen retrieval
Antigen retrieval was accomplished using the following procedures. Prepared tissues were immunostained according to the avidin-biotin complex pro~edure.~' Avidin and biotinylated peroxidase (Vectastain Elite kit PK 6 102, Vector Laboratories, Burlingame, CA) and biotinylated horse antimouse antibody (Vector Laboratories) served as the detection system. The chromogen was 3,3' diaminobenzidine tetrahydrochloride (DAB, Sigma Chemical Co.).
Formalin-fixed sections were deparaffinized and rehydrated through sequential immersions in xylene followed by changes of graded concentrations of ethanol. Sections were then rinsed in distilled water. Endogenous peroxidase activity was quenched by immersion of the slides in 3% hydrogen peroxide diluted in phosphate-buffered saline (PBS) for 10 minutes followed by rinsing in PBS. Tissue sections were then incubated in preheated (90 C) target unmasking fluid (TUF, Signet Laboratories) diluted in PBS (1 : 3) for 10 minutes as a means of unmasking antigens. Nonimmune binding of antiserum was blocked by incubating sections in PBS supplemented with 4% normal horse serum (1 : 10 dilution) for 20 minutes. Each tissue section was incubated overnight with the primary antiserum for each monoclonal antibody properly diluted in PBS containing 4% equine serum. After rinsing, slides were incubated for 45 minutes with biotinylated horse anti-mouse antibody prepared according to the Vectastain Elite ABC kit directions. PBS-washed sections were then incubated for 60 minutes in the avidin-biotin complex peroxidase solution made according to the manufacturer's directions and again washed in PBS. Slides were developed for 5 minutes in a solution of DAB (50 mg/250 ml) in PBS supplemented with hydrogen peroxide (3 drops of 3%). Final steps consisted of rinsing in PBS, counterstaining with hematoxylin, clearing, and mounting. All incubations were carried out at room temperature. The positive control tissue consisted of a formalin-fixed, paraffin-embedded section of human hepatocellular carcinoma (Fig. 1 ). This tissue was originally stained according to the above procedure with the omission of the antigen retrieval step. Negative controls (selected sections of the above described tissues) were run in parallel, substituting the monoclonal antibody to P-gly with normal mouse ascites fluid diluted in PBS in the same manner as the primary antibody (Fig. 2) .
Microscopic evaluation
All tissue sections were evaluated with a light microscope to determine the presence and cellular location of positive immunostaining. Staining was designated as membranous/ apical or cytoplasmic and as focal, multifocal, or diffuse within the tissue.
Results
Immunohistochemical detection of P-gly in formalin-fixed, paraffin-embedded tissues was best accomplished with overnight primary antibody incubations and an antigen retrieval system. Implementation of an antigen retrieval system increased the number of cells labeled and the intensity of the label in serially stained sections. The antigen retrieval system also allowed higher antibody dilutions to be used without losing intense specific labeling. Primary antibody dilutions for C494 and C219 of 1 : 200 and 1 : 20, respectively, produced sections with no or minimal background and clear detection of specific labeling. Repeated attempts to maintain and improve the intensity of labeling with JSB-1 in both the human hepatocellular carcinoma control and normal canine liver while eliminating background staining were not successful. A final primary antibody dilution of 1 : 20 coupled with the antigen retrieval system produced the best results deemed possible with JSB-1 in our laboratory (Fig. 3) .
Normal tissues with consistent positive labeling for P-gly with all three monoclonal antibodies
Liver. Multifocal to diffuse mild to intense, discrete labeling of canalicular surfaces of hepatocytes with occasional outlining of the entire hepatocyte were consistent findings with C494 and C219 (Fig. 4) . JSB-1 weakly labeled the entire hepatocyte cytoplasm throughout the liver, with some hepatocytes having more discrete labeling of canalicular surfaces. This staining pattern produced by JSB-1 was similar to that noted with the human hepatocellular carcinoma stained with JSB-1. Biliary epithelium labeled multifocally intensely along the apical surface with all three antibodies. Overall intensity and specificity of labeling were best with C494 and C2 19. Background and less intense staining were noted with JSB-1.
Adrenal gland. Cells of the adrenal cortex labeled diffusely within the cytoplasm with all three antibodies. Some cells had intensely labeled cell borders and/ o r prominent perinuclear intensely stained foci. Cells of the adrenal medulla did not label with any of the antibodies.
Stomach. Parietal cells within the gastric glands labeled diffusely within the cytoplasm with intense cell borders with all three antibodies. Apical margins of the gastric epithelium labeled intensely with C494.
Pancreas. Ductular epithelium stained diffusely within the cytoplasm with all three antibodies. Discrete, intensely labeled apical margins of ductular epithelium and outlines of some acinar cells were noted with C494.
Colon. Colonic epithelium labeled multifocally within the cytoplasm of absorptive cells, with most intense and discrete labeling of apical surfaces of enterocytes elicited with C494 (Fig. 5) . C219 and JSB-1 stained the enterocyte cytoplasm less intensely and did not label the apical surfaces of the enterocytes as often o r as discretely as did C494. JSB-1 results were complicated by background staining.
Kidney. Renal tubular epithelium stained multifocally throughout the kidney with all three antibodies. Proximal tubular epithelium stained most often and most intensely; however, distal tubular epithelium and loops of Henle also stained. The cytoplasm labeled diffusely with C494 eliciting a more intensely stained luminal border within the proximal tubular epithelium (Fig. 6) . Occasionally, the basal or lateral aspects of the cells would label more intensely than the cytoplasm with C494. Staining with C2 19 and JSB-1 was weaker and more multifocal, with no distinct luminal margins. Uroepithelium of the renal papillae labeled intensely within the cytoplasm with C494 and JSB-1.
Salivary gland ducts. Ducts of the mandibular salivary gland stained diffusely within the cytoplasm with all three antibodies. More intensely labeled apical margins were detected with C494. Colon; dog. Antibodies for P-glycoprotein labeled the apical margins of absorptive enterocytes intensely. Avidinbiotin-peroxidase complex method, C494 monoclonal antibody, Mayer's hematoxylin counterstain. Bar = 10 pm.
Kidney; dog. Intense labeling of luminal aspects of renal proximal tubular epithelium with occasional labeling of basal or lateral cell margins was a consistent pattern in the kidney. Avidin-biotin-peroxidase complex method, C494 monoclonal antibody, Mayer's hematoxylin counterstain. Bar = 10 pm.
Hepatoma; dog. Neoplastic hepatocytes labeled at points of cell-to-cell contact with variable intensity throughout the tumor. Avidin-biotin-peroxidase complex method, C494 monoclonal antibody, Mayer's hematoxylin counterstain. Bar = 10 pm.
Mammary gland adenocarcinoma; dog. Neoplastic epithelial cells labeled diffusely within the cytoplasm with multifocal accentuation of cell margins with the P-glycoprotein monoclonal antibodies. Avidin-biotin-peroxidase complex method, C494 monoclonal antibody, Mayer's hematoxylin counterstain. Bar = 10 pm. Lung. Apical margins of bronchial/bronchiolar epithelium and alveolar lining cells labeled with all three antibodies.
Brain. Capillary endothelial cells of the brain labeled at the lumenal margins with all three antibodies.
Endothelium. Endothelial cells were outlined by all three antibodies within some sections of the superficial dermis and within some areas of some tumors.
Normal tissues with variable staining for P-gly
Myocardium. Subtle and diffuse labeling was present with C494 and JSB-1.
Mammary gland. C494 and JSB-1 multifocally faintly stained mammary gland epithelium diffusely within the cytoplasm and more intensely at the apical margins.
Apocrine glands. Cytoplasm and apical margins of some apocrine glands of the skin labeled intensely with Sebaceous glands. Sebaceous epithelial cells were labeled at the cytoplasmic margins with JSB-1 in some sections of skin.
Stratified squamous epithelium. Scattered cells labeled diffusely within the cytoplasm with C219 and JSB-1 in the epidermis and esophagus.
Uterus. The apical margins of the endometrium labeled with JSB-1. multifocally within the cytoplasm with JSB-1.
N e o p 1 as m s
A total of 166 neoplasms were analyzed for P-gly expression. Of these, 66 (39.8%), 53 (31.9%), and 38 (22.9%) neoplasms labeled for P-gly with C494, JSB-1, and C219, respectively (Table 4) . Comparison of results of immunostaining for each antibody yielded a high degree of concurrence for each tumor group (Table  5) . For example, 12 mammary gland carcinomas were labeled. Eight were positive for two of the antibodies, with six of the eight positive for all three monoclonal antibodies. Two were positive with only JSB-1 and one was positive only with C494. P-gly was not detected by C2 19 in any tumor that was not also positive for P-gly with either C494 or JSB-I. C494 detected P-gly in more neoplasms than did either C2 19 or JSB-1.
Tumors arising from tissues with intrinsic P-gly expression consistently labeled for P-gly in a cellular pattern identical to that described for the tissue in the nonneoplastic state. Hepatomas had diffuse, intense labeIing of tumor ceIl margins at points of cell-to-cell contact (Fig. 7) . Tumor cell emboli within lymphatic vessels found in colonic carcinomas frequently labeled Vet Paihol 3 3 5 , 1996
Detection of P-glycoprotein 539 monoclonal antibodies.* at the cytoplasmic margins. Labeling of mammary gland tumors was multifocal within the tumor section, occurring diffusely within the cytoplasm of neoplastic epithelium with multifocal more intense labeling of the cytoplasmic margins (Fig. 8) .
In hemangiopericytomas, the tumor tissue was diffusely labeled with C494 distinctly outlining tumor cell margins. Positive cases of malignant lymphoma had multifocal clusters of tumor cells labeled within the cytoplasm. Neoplastic cells within malignant melanomas, basal cell tumors, leiomyosarcomas, squamous cell carcinomas, apocrine gland adenomas, and thyroid gland tumors labeled multifocally; tumor cell cytoplasm was diffusely stained, often seen accompanied by intense labeling of cytoplasmic margins.
Cutaneous plasma cell tumors, histiocytomas, fibromas, fibrosarcomas, and leiomyomas did not label with any of the three antibodies.
Discussion
This study indicates that P-gly can be detected in routinely processed canine tissues via immunohistochemical methods using commercially available antibodies. C494 appears to be the antibody of choice for use in canine tissues, based on quality of staining produced, specificity (specific for mdrl), and the economic advantage of using higher dilutions. This antibody also labeled more neoplasms than did either C2 19 or JSB-1. Some neoplasms expressing P-gly might be missed if only evaluated with C494; JSB-1 labeled an additional nine (5.4%) tumors that had not been labeled by C494. The C2 19 antibody did not label any tumors not also labeled by either C494 or JSB-1. Failure of some tumors to label with C219 antibody may be a result of the adverse effect of fixation and tissue processing. The suitability of C219 antibody for use in formalin-fixed, paraffin-embedded tissues is controversial. Numerous reports document detection of P-gly in formalin-fixed, paraffin-embedded t i~s u e s .~~~~ One report compared the use of C2 19 antibody in frozen and formalin-fixed, paraffin-embedded human tissues and found results to be comparable and not significantly reduced by formalin fixation.6 Another investigator reported adverse effects of heat and xylene on the C2 19 e p i t~p e .~* The actual titers of C2 19 antibody vary significantly from lot to lot, and this variation coupled with the variety of procedures in different laboratories may account for these dis~repancies.~~ Re-Ginn Vet Pathol335, 1996 sults of this study suggest that evaluating formalinfixed, paraffin-embedded tumors for epitopes recognized by C2 19 may not yield additional useful information. The tissue distribution and cellular location of P-gly expression in normal canine tissues is very similar to that in humans, with the liver, colon, kidney, and adrenal cortex being consistently and intensely labeled.13Js,34 This study indicates that P-gly expression in canine neoplasms is comparable to that in human tumors in that intrinsic expression of P-gly occurs in tumors of the liver, colon, and adrenal gland.13Js, 35 Although the number of neoplasms of a given type examined for P-gly expression in this study was too small to allow prediction of P-gly expression for a particular type of tumor, P-gly expression of untreated canine malignant lymphomas, mammary gland carcinomas, melanomas, and thyroid carcinomas yielded mixed results, which is consistent with P-gly expression in the same tumors in hurnans.l3 The consistent, intense reactivity of hemangiopericytomas with C494 and absence of labeling with either C2 19 or JSB-1 was unexpected. Canine hemangiopericytomas are known to be intrinsically resistant to chemotherapy and might be expected to express P-gly, but cross-reactivity of C494 with an antigen other than P-gly expressed by the malignant pericytes cannot be excluded.
Results of this study support the presence of P-gly in canine tumors and the hypothesis that apparent mechanisms of multidrug resistance in the dog are similar to those proposed for humans. We attempted to establish a procedure for use in routinely processed clinical specimens. Confirmation of the existence and significance of P-gly expression in canine tissues would require additional procedures to identify and quantitate the protein and correlate levels with response to treatment. This study also illustrates the fact that P-gly expression is not limited to malignant tumors. Maintenance of expression of P-gly by tumors arising from tissues with intrinsic P-gly expression could be an indication of differentiation and could impact prognosis. Identification of a subgroup of similar tumors with low or no P-gly expression could be an indication of tumor progression and serve as a negative influence upon prognosis. Alternatively, a recent study indicated tumor cell upregulation of the multidrug resistant gene with mutations in Ras and with loss of normal p53 tumor suppressor gene function, both documented molecular events in tumor progression. lO The P-gly molecule confers drug resistance in cell culture to a wide variety of cytotoxic agents commonly in use in clinical oncology, e.g., the Vinca alkaloids (vinblastine and vincristine), anthracyclines, and actinomycin D.Is Canine malignant lymphoma is commonly treated with both the Vznca alkaloids and anthracyclines, often with initial success later followed by resistance to these drugs.21 Tumor cell drug resistance in canine malignant lymphoma is speculated to be due to the expression of P -g l~.~ Mammary gland and thyroid carcinomas, mast cell tumors, hemangiosarcomas, and a wide variety of other sarcomas and carcinomas in veterinary patients are often treated with chemotherapeutic agents affected by the multidrug resistant gene. 26 The detection of P-gly in routinely processed veterinary surgical biopsy specimens will form the basis of further long-term collaborative clinical studies. This research will determine the significance of P-gly expression and factors contributing to the development of its expression. Reversibility of drug resistance attributed to P-gly expression and early detection of nonresponsive disease are other potential applications. These subjects are now being investigated in human subjects with particular emphasis on use of specialized drug carriers and pharmaceuticals designed to bypass or reverse P-gly-mediated drug resi~tance.~J 1~15,20,22,23,30 The results of these investigations may benefit veterinary patients. In turn, data collected from studies in dogs with tumors comparable to those of humans may serve as animal models for human disease.
